Pure Global: Brazil's MDSAP Fast-Track for MedTech Success

This week on MedTech Global Insights, we explore a game-changing regulatory update from Brazil. ANVISA's new Resolution RDC 850/2024 allows medical device manufacturers to leverage their MDSAP certificate to extend the validity of their Brazil GMP certification, drastically simplifying market access. This move is a powerful signal of the growing trend toward global regulatory harmonization. We discuss how MedTech companies can turn this trend into a significant competitive advantage, using a single audit process to unlock multiple international markets faster and more efficiently than ever before. Case Study Highlight: A U.S.-based device manufacturer has full MDSAP certification. They've been hesitant to enter the complex Brazilian market due to the notoriously slow and expensive B-GMP audit process. How does this new resolution change their entire expansion timeline and budget overnight? Key Takeaways This Episode: - What exactly is Brazil's Resolution RDC 850/2024 and who does it apply to? - How can leveraging an MDSAP certificate reduce audit fatigue and costs for your business? - Is this part of a larger global trend, and which other countries are moving in this direction? - What are the strategic implications for your company's global registration planning? - How does this change the return on investment for pursuing MDSAP certification? - Can this strategy be applied to other regions beyond Latin America? Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.